Multidimensional single-cell approach probing HIV-1 integration association with non-AIDS defining cancers (Biospecimens/Biocohort)
Multidimensional single-cell approach probing HIV-1 integration association with non-AIDS defining cancers (Biospecimens/Biocohort)
批准号:
10619156
负责人:
Carlos L Arteaga
金额:
$25.0万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
未结题
起止时间:
2010-09-01 至 2026-07-31
关键词:
Acquired Immunodeficiency SyndromeB-Cell LymphomasB-LymphocytesBehaviorBiological MarkersCD4 Positive T LymphocytesCell ProliferationCellsClinicClinicalClonal ExpansionData SetDiagnosticDown-RegulationEventFutureGene ExpressionGene Expression AlterationGene Expression ProfileGenesGenomicsGoalsHIV-1HandHumanHuman GenomeIncidenceIndividualInfectionKnowledgeLinkLocationMalignant NeoplasmsMapsMinorMolecularOncogenesOutcomeParticipantPatientsPatternPersonsPlayPrevalenceProto-OncogenesProvirusesRNA SplicingResearch ProposalsRoleSecondary toSiteT-LymphocyteTestingTherapeuticTimeTumor Suppressor ProteinsUp-RegulationVirusVirus IntegrationVirus ReplicationWorkantiretroviral therapybehavioral phenotypingcancer initiationcancer specimen resourceclinical decision-makingcohortin vivoinnovationintegration siteprognosticprogramssingle-cell RNA sequencingtranscriptometumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Current treatments for HIV-1 infection include suppressive anti-retroviral therapy (ART), which curtails
active viral replication to nearly undetectable levels. However, ART fails to cure HIV-1 infection because the
virus persists indefinitely in a latent state. While people living with HIV-1 (PLWH) live longer, they are subject to
secondary long-term consequences due to the ART regime itself and the presence of integrated proviruses
throughout the human genome. Whereas ART facilitated a decrease in the incidence of AIDS defining cancers,
an increased incidence of non-AIDS defining cancers (NADC), such as T and B cell lymphomas, has been well
documented in the clinics. Despite previous controversies regarding the role of HIV-1 integration site and
cancer prevalence, the clinical association between HIV-1 integration in defined sites and NADC prevalence
remains largely unexplored. Given these previous findings and gaps in knowledge, the central hypothesis of
this proposal is that HIV-1 integration into or nearby select human genes alters their expression thereby
causing NADC. Specifically, HIV-1 integration might disrupt the normal expression of HIV-1 Associated GEnes
(HAGEs) causing upregulation of proto-oncogenes, downregulation of tumor suppressors and/or altering RNA
splicing patterns, consequently rewiring gene expression programs producing abnormal CD4+ T and B cell
expansion and/or behaviors leading to NADC.
The major goal of this proposal is to interrogate whether select HIV-1 integration sites are associated with
increased incidence of NADC in PLWH under suppressive therapy and to predict associated biomarkers. To
start accomplishing this goal, we will deploy a multidimensional approach to concurrently profile HIV-1
integration sites and human transcriptomes at the single cell level in a unique cohort available through the
AIDS and Cancer Specimen Resource (ACSR). This will be the first ever approach that can simultaneously
interrogate the relationship between HIV-1 integration sites and human transcriptomes at the single cell level in
participants biospecimens. We already have on hand an impressive molecular and genomic toolset that will be
strategic for accomplishing the Specific Aims of this proposal. These include: 1) To deploy a multidimensional
single cell approach to simultaneously collect HIV-1 integration sites and human transcriptomes in ACSR
participants biospecimens (Aim 1), and 2) to combine the generated datasets to define participants HIV-1
integration-induced biomarkers associated with NADC (Aim 2). Collectively, these studies will reveal viral
integration sites over-represented in PLWH with NADC, link individual viral integration sites to altered human
gene expression potentially explaining the onset of NADC, and categorize biomarkers linked to select HIV-1
integration events for diagnostic and prognostic outcomes. Future studies using this knowledge will functionally
define specific HIV-1 integration events as NADC drivers and help devise alternative therapeutic opportunities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
-
批准号:10660734
-
项目类别:
-
资助金额:$51.03万
-
财政年份:2023
-
负责人:Carlos L Arteaga
-
依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
-
批准号:9759820
-
项目类别:
-
资助金额:$35.74万
-
财政年份:2018
-
负责人:Carlos L Arteaga
-
依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
-
批准号:10214565
-
项目类别:
-
资助金额:$36.83万
-
财政年份:2018
-
负责人:Carlos L Arteaga
-
依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
-
批准号:10458531
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2018
-
负责人:Carlos L Arteaga
-
依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
-
批准号:9614453
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2018
-
负责人:Carlos L Arteaga
-
依托单位:
Admin/Outreach Core
-
批准号:8947587
-
项目类别:
-
资助金额:$7.77万
-
财政年份:2014
-
负责人:Carlos L Arteaga
-
依托单位:
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br
-
批准号:8764757
-
项目类别:
-
资助金额:$27.75万
-
财政年份:2014
-
负责人:Carlos L Arteaga
-
依托单位:
Developmental Research Program
-
批准号:8764765
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2014
-
负责人:Carlos L Arteaga
-
依托单位:
Career Development Program
-
批准号:8764766
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2014
-
负责人:Carlos L Arteaga
-
依托单位:
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
-
批准号:10693201
-
项目类别:
-
资助金额:$430.61万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
-
批准号:10170609
-
项目类别:
-
资助金额:$430.61万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
-
批准号:10477948
-
项目类别:
-
资助金额:$430.61万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Developmental Funds
-
批准号:10477999
-
项目类别:
-
资助金额:$47.07万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Addressing Colonoscopy Quality to Increase Capacity for Colorectal Cancer Screening (CCSG YR13)
-
批准号:10893842
-
项目类别:
-
资助金额:$4.93万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Cancer Center Administration Core
-
批准号:10703661
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Population Science and Cancer Control Scientific Program
-
批准号:10260732
-
项目类别:
-
资助金额:$2.82万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
PLANNING AND EVALUATION (Core-001)
-
批准号:10260746
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Administrative Core and Senior Leadership
-
批准号:10260747
-
项目类别:
-
资助金额:$23.61万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Cancer Center Administration Core
-
批准号:10693202
-
项目类别:
-
资助金额:$43.7万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Leadership, Planning, and Evaluation
-
批准号:10170620
-
项目类别:
-
资助金额:$56.26万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
海外基金